ACRP Webinar: Regulatory Concerns When Running Paperless Clinical Trials

On March 7, 2018, Jonathan Helfgott (formerly at FDA) and Jules Mitchel (President of Target Health Inc.) will be presenting an ACRP Webinar entitled: “Regulatory Concerns When Running Paperless Clinical Trials.“ Here is a summary:


The FDA and other regulatory bodies have issued multiple guidance documents addressing requirements when using technology tools to execute paperless clinical trials. The push from the regulatory agencies has occurred despite a risk-averse pharmaceutical industry, still conflicted about living in a “paper world.“ This risk aversion is in part due to an irrational fear by sites and sponsors of receiving a FDA Form 483 when an FDA inspector discovers that a patient was born in 1982, when in the study database it is recorded as 1983; and it did not matter. Additionally, the clinical sites are also fearful of losing business as a result of any FDA Form 483 finding, however minor.


The following are examples of regulated clinical trial software: 1) Data capture (EDC) systems; 2) Electronic informed consent; 3) Electronic trial master file (eTMF): 4) ePRO and eCOA; 5) Dedicated tablets collecting and storing data in real time; 6) Mobile Apps; and 7) Web-based systems collecting data in real time which transmit the data to the study database only after the source record is securely received and stored in an independent eSource storage location under control of the study site.


Upon completion of this Webinar, attendees should be able to:


1.     Understand the future landscape of paperless clinical trials

2.     Understand regulatory concerns when running paperless clinical trials

3.     How to “separate toys from tools“ when choosing mobile and related devices


For more information about Target Health contact Warren Pearlson (212-681-2100 ext. 165). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel. The Target Health software tools are designed to partner with both CROs and Sponsors. Please visit the Target Health Website.


Joyce Hays, Founder and Editor in Chief of On Target

Jules Mitchel, Editor



Filed Under News | Leave a Comment

Pancreatic Islet Transplantation

The process of clinical islet transplantation for the treatment of diabetes mellitus

Graphic credit: Giovanni Maki – Naftanel MA, Harlan DM (2004) Pancreatic Islet Transplantation. PLoS Med 1(3): e58 (image link), CC BY 2.5,


Islet transplantation is the transplantation of isolated islets from a donor pancreas into another person. It is an experimental treatment for type 1 diabetes mellitus. Once transplanted, the islets begin to produce insulin, actively regulating the level of glucose in the 1) ___. Islets are usually infused into the patient’s liver. If the cells are not from a genetically identical donor the patient’s body will recognize them as foreign and the immune system will begin to attack them as with any transplant rejection. To prevent this, immunosuppressant 2) ___ are used. Recent studies have shown that islet transplantation has progressed to the point that 58% of the patients in one study were insulin independent one year after the operation.


The concept of islet transplantation is not new. Investigators as early as the English surgeon Charles Pybus (1882-1975) attempted to graft pancreatic tissue to cure diabetes. Most, however, credit the recent era of islet transplantation research to Paul Lacy’s studies dating back more than three decades. In 1967, Lacy’s group described a novel collagenase-based method to isolate islets, paving the way for future in vitro and in vivo islet experiments. Subsequent studies showed that transplanted islets could reverse diabetes in both rodents and non-human primates. In a summary of the 1977 Workshop on Pancreatic Islet Cell Transplantation in Diabetes, Lacy commented on the feasibility of “islet cell transplantation as a therapeutic approach [for] the possible prevention of the complications of diabetes in man“. Improvements in isolation techniques and immunosuppressive regimens ushered in the first human islet transplantation clinical trials in the mid-1980s.


The first successful trial of human islet allotransplantation resulting in long-term reversal of 3) ___ was performed at the University of Pittsburgh in 1990. Yet despite continued procedural improvements, only about 10% of islet recipients in the late 1990s achieved euglycemia (normal blood glucose). In 2000, Dr. James Shapiro and colleagues published a report describing seven consecutive patients who achieved euglycemia following islet transplantation using a steroid-free protocol and large numbers of donor islets, since referred to as the Edmonton protocol. This protocol has been adapted by islet transplant centers around the world and has greatly increased islet transplant success. The goal of islet transplantation is to infuse enough islets to control the blood glucose level removing the need for 4) ___ injections. For an average-size person (70 kg), a typical transplant requires about one million islets, isolated from two donor pancreases. Because good control of blood glucose can slow or prevent the progression of complications associated with diabetes, such as nerve or eye damage, a successful transplant may reduce the risk of these complications. But a transplant recipient will need to take immunosuppressive drugs that stop the immune system from rejecting the transplanted islets. A mixture of highly purified enzymes (Collagenase) is used to isolate islets from the pancreas of a deceased donor. Collagenase solution is injected into the pancreatic duct which runs through the head, body and tail of the pancreas. Delivered this way, the enzyme solution causes distension of the pancreas, which is subsequently cut into small chunks and transferred into so-called Ricordi’s chamber, where digestion takes place until the islets are liberated and removed from the solution. Isolated islets are then separated from the exocrine tissue and debris in a process called purification. During the transplant, a radiologist uses ultrasound and radiography to guide placement of a catheter through the upper abdomen and into the portal vein of the liver. The islets are then infused through the 5) ___ into the liver. The patient will receive a local anesthetic. If a patient cannot tolerate local anesthesia, the surgeon may use general anesthesia and do the transplant through a small incision. Possible risks of the procedure include bleeding or blood clots.


In 2000, the Edmonton protocol used a combination of immunosuppressive drugs, including daclizumab (Zenapax), sirolimus (Rapamune) and tacrolimus (Prograf). Daclizumab is given intravenously right after the transplant and then discontinued. Sirolimus and tacrolimus, the two main drugs that keep the immune system from destroying the transplanted islets, must be taken for life. While significant progress has been made in the islet transplantation field, many obstacles remain that currently preclude its widespread application. Two of the most important limitations are the currently inadequate means for preventing islet rejection, and the limited supply of islets for transplantation. Current immunosuppressive regimens are capable of preventing islet failure for months to years, but the agents used in these treatments are expensive and may increase the risk for specific malignancies and opportunistic infections. Perhaps of greatest concern to the patient and physician is the harmful effect of certain widely employed immunosuppressive agents on renal function. For the patient with diabetes, renal function is a crucial factor in determining long-term outcome, and calcineurin inhibitors (tacrolimus and ciclosporin) are significantly nephrotoxic. Thus, while some patients with a pancreas transplant tolerate the immunosuppressive agents well, and for such patients diabetic nephropathy can gradually improve, in other patients the net effect (decreased risk due to the improved blood glucose control, increased risk from the immunosuppressive agents) may worsen kidney function. Indeed, Ojo et al. have published an analysis indicating that among patients receiving other-than-kidney allografts, 7%-21% end up with renal 6) ___ as a result of the transplant and/or subsequent immunosuppression. Seen another way, patients with heart, liver, lung, or kidney failure have a dismal prognosis for survival, so the toxicity associated with immunosuppression is warranted (the benefits of graft survival outweigh the risks associated with the medications). But for the subset of patients with diabetes and preserved kidney function, even those with long-standing and difficult-to-control disease, the prognosis for survival is comparatively much better.


Like all transplantation therapies, islet transplantation is also handicapped by the limited donor pool. The numbers are striking; at least 1 million Americans have type 1 diabetes mellitus, and only a few thousand donors are available each year. To circumvent this organ shortage problem, researchers continue to look for ways to “grow“ islets – or at least cells capable of physiologically regulated insulin secretion – in vitro, but currently only islets from cadaveric donors can be used to restore euglycemia. Further exacerbating the problem (and unlike kidney, liver, and heart transplants, where only one donor is needed for each recipient) most islet transplant patients require islets from two or more donors to achieve euglycemia. Lastly, the current methods for islet isolation need improvement, since only about half of attempted isolations produce transplant-ready islets.


While islet transplantation research has made important progress and the success stories are encouraging, the long-term safety and efficacy of the procedure remain unclear. Other concerns relating to the field include questions about the impact of having insulin-producing foreign cells within the hepatic parenchyma, the long-term consequences of elevated portal pressures resulting from the islet infusion, and the fact that islet recipients can be sensitized against donor tissue types, making it more difficult to find a suitable donor should another life-saving transplant be required in the future. Also, very few islet transplant recipients have remained euglycemic without the use of any exogenous insulin beyond four years post-transplant. Thus, while most islet recipients achieve better glycemia control and suffer less serious hypoglycemia, islet transplantation continues to fall short of the definitive diabetes cure. Pancreatic islet 7) ___ has been reappraised based on accumulated clinical evidence. Although initially expected to therapeutically target long-term insulin independence, islet transplantation is now indicated for more specific clinical benefits. With the long-awaited report of the first phase 3 clinical trial in 2016, allogeneic islet transplantation is now transitioning from an experimental to a proven therapy for type 1 diabetes with problematic hypoglycemia. Islet autotransplantation (IAT) has already been therapeutically proven in chronic pancreatitis with severe abdominal pain refractory to conventional treatments, and it holds promise for preventing diabetes after partial pancreatectomy due to benign pancreatic tumors. Based on current evidence, this review focuses on islet transplantation as a realistic approach to treating diabetes. Recently, the French-Swiss GRAGIL Network successfully reproduced the long-term outcome achieved with the Edmonton protocol in terms of the graft survival rate (~80%), with a 58% rate of HbA1c levels at < 7% and lack of severe hypoglycemia 5 years after islet transplantation . Several cases of partial islet graft function have also been reported in Korea (ROK). Studies revealed that the islet yield and islet function in this clinical setting was superior to those of allogeneic islet transplantation, in which islets are isolated from brain-dead donors . Additionally, it was showed that transplanted islets can promote the regeneration of endogenous beta-cells in experimental models of IAT after partial pancreatectomy. In summary, IAT after partial pancreatectomy for benign tumors could be a promising indication for clinical islet transplantation. In this setting, IAT may improve the metabolic milieu after pancreatic resection and offers a unique opportunity to understand the biological effects of intraportal islet transplantation beyond the simple replacement of islet cell mass. Recent results from international cohort studies and the phase 3 clinical trial of allogeneic islet transplantation prompt reappraisal of this method as an important component of the stepwise approach to the treatment of problematic hypoglycemia. The 5-year insulin-independence rate of islet transplantation patients has also improved at some experienced centers. IAT has already been proven to be an effective therapy for intractable pain due to advanced chronic pancreatitis. Partial pancreatectomy for the treatment of benign pancreatic 8) ___ could be another indication for the use of IAT in the near future.


Successful islet 9) ___ transplantation can provide the following benefits:


1. Restore or improve the body’s ability to regulate blood sugar levels. The need for frequent blood sugar measurements and daily insulin injections can be reduced, and in a minority of patients, eliminated three years after transplantation. Although being free from insulin injections may only last several months or a year, islet cell transplantation reduces episodes of low blood sugar for a longer time.

2. Improve the quality of life.

3. Reduce the progression of long-term complications of diabetes, including heart disease, kidney disease, stroke, and nerve and eye damage.


Because it is still considered an experimental therapy, islet cell transplantation for diabetes is not widely available. There are currently 17 U.S. centers participating in islet cell research programs. The American Diabetes Association recommends that pancreas or islet cell transplantation be performed only in certain major centers, which are best equipped to handle the complex and long-term medical and personal needs of transplant patients. Collecting enough islet cells to do the transplant: Obtaining enough islet cells for transplantation is a major challenge. In most cases, islet cells from several different donors are needed. Because the need surpasses the number of human donors available, researchers are studying the use of cells from other sources, including fetal tissue and animals such as pigs. Researchers are also attempting to grow human islet cells in the laboratory. Preventing rejection: Researchers are continuously seeking to develop new and better anti-rejection drugs. Many advances have been made in anti-rejection 10) ___ over the past 15 years. Newer drugs — such as tacrolimus (FK506) and rapamycin — have fewer and less harmful side effects than some older drugs like cyclosporine and prednisone. Researchers are also working to develop methods of transplanting islet cells that will reduce or eliminate the risk of rejection and the need for immunosuppression. One approach involves coating the islet cells with a special gel that prevents the immune system from recognizing and targeting the donor cells.

Sources: Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI13C0954); Sang-Man Jin1 and Kwang-Won Kim2…/type-1-diabetes-islet-transplantation-gains-momentum.



ANSWERS: 1) blood; 2) drugs; 3) diabetes; 4) insulin; 5) catheter; 6) failure; 7) transplantation; 8) tumors; 9) cell; 10) drugs



Please open up this video so that this serves as the graphic for the article


The discovery of clustered DNA repeats began independently in three parts of the world. One of the first discoveries was in 1987 at Osaka University in Japan. Researcher Yoshizumi Ishino and colleagues published their findings on the sequence of a gene called “iap“ and its relation to E. coli. Technological advances in the 1990s allowed them to continue their research and speed up their sequencing with a technique called metagenomics. They were able to collect seawater or soil samples and sequence the DNA in the sample. The first description of what would later be called CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), occurred in 1987 when Yoshizumi Ishino accidentally cloned part of a CRISPR together with the iap gene, the target of interest. The organization of the repeats was unusual because repeated sequences are typically arranged consecutively along DNA. The function of the interrupted clustered repeats was not known at the time.


Ishino received his BS, MS and PhD degree in 1981, 1983 and 1986, respectively, from Osaka University. From 1987 to 1989, he was a post-doctoral fellow at Yale University (Dieter Soll’s laboratory). In 2002, he became a professor at Kyushu University. Since October 2013, he is also a member of the NASA Astrobiology Institute, University of Illinois at Urbana-Champaign.


In 1993 researchers of Mycobacterium tuberculosis in the Netherlands published two articles about a cluster of interrupted direct repeats (DR) in this bacterium. These researchers recognized the diversity of the DR-intervening sequences among different strains of M. tuberculosis and used this property to design a typing method that was named spoligotyping, which is still in use today. At the same time, repeats were observed in the archaeal organisms of Haloferax and Haloarcula species, and their function was studied by Francisco Mojica at the University of Alicante in Spain. Although his hypothesis turned out to be wrong, Mojica surmised at the time that the clustered repeats had a role in correctly segregating replicated DNA into daughter cells during cell division because plasmids and chromosomes with identical repeat arrays could not coexist in Haloferax volcanii. Transcription of the interrupted repeats was also noted for the first time. Transcription of the interrupted repeats was also noted for the first time. In 2017 Mojica was a winner of the Albany Medical Center Prize.


The three articles below, are well written and informative regarding this new and exciting technology.–A-Conversation-with-George-Church/


Eye Imaging Could Provide “Window to the Brain“ After Stroke

According to an article published in Neurology (7 February 2018), research into curious bright spots in the eyes on stroke patients’ brain images could one day alter the way these individuals are assessed and treated. A team of scientists at the NIH found that a chemical routinely given to stroke patients undergoing brain scans can leak into their eyes, highlighting those areas and potentially providing insight into their strokes. The eyes glowed brightly on those images due to gadolinium, a harmless, transparent chemical often given to patients during magnetic resonance imaging (MRI) scans to highlight abnormalities in the brain. In healthy individuals, gadolinium remains in the blood stream and is filtered out by the kidneys. However, when someone has experienced damage to the blood-brain barrier, which controls whether substances in the blood can enter the brain, gadolinium leaks into the brain, creating bright spots that mark the location of brain damage.


Previous research had shown that certain eye diseases could cause a similar disruption to the blood-ocular barrier, which does for the eye what the blood-brain barrier does for the brain. The authors discovered that a stroke can also compromise the blood-ocular barrier and that the gadolinium that leaked into a patient’s eyes could provide information about his or her stroke.


The authors performed MRI scans on 167 stroke patients upon admission to the hospital without administering gadolinium and compared them to scans taken using gadolinium two hours and 24 hours later. Because gadolinium is transparent, it did not affect patients’ vision and could only be detected with MRI scans. Roughly three-quarters of the patients experienced gadolinium leakage into their eyes on one of the scans, with 66% showing it on the two-hour scan and 75% on the 24-hour scan. The phenomenon was present in both untreated patients and patients who received a treatment, called tPA, to dissolve the blood clot responsible for their strokes. Gadolinium was typically present in the front part of the eye, called the aqueous chamber, after two hours, and in a region towards the back, called the vitreous chamber, after 24 hours. Patients showing gadolinium in the vitreous chamber at the later timepoint tended to be of older age, have a history of hypertension, and have more bright spots on their brain scans, called white matter hyperintensities, that are associated with brain aging and decreased cognitive function.


In a minority of patients, the two-hour scan showed gadolinium in both eye chambers. The strokes in those patients tended to affect a larger portion of the brain and cause even more damage to the blood-brain barrier than the strokes of patients with a slower pattern of gadolinium leakage or no leakage at all. The findings raise the possibility that, in the future, clinicians could administer a substance to patients that would collect in the eye just like gadolinium and quickly yield important information about their strokes without the need for an MRI.


According to the authors, it is much easier for us to look inside somebody’s eye than to look into somebody’s brain, so if the eye truly is a window to the brain, we can use one to learn about the other. Despite the relationship between gadolinium leakage and stroke severity, the phenomenon was not found to be related to the level of disability the patients developed following their strokes. It also remains unclear whether gadolinium can enter the eye in healthy people.


Ebola Virus Infects Reproductive Organs in Monkeys

According to an article published in the American Journal of Pathology (8 February 2018), Ebola virus can infect the reproductive organs of male and female macaques, suggesting that humans could be similarly infected. Prior studies of survivors of the 2014-2016 Ebola outbreak in West Africa have revealed that viral RNA (Ebola virus genetic material) can persist in male and female human reproductive tracts following recovery. While little is known about viral persistence in female reproductive tissues, pregnant women with Ebola virus disease have a maternal death rate of more than 80% and a fetal death rate of nearly 100%.

For the study, four female and eight male macaques were infected with the Makona variant of Ebola virus, the variant responsible for the recent West Africa outbreak. All the macaques succumbed to Ebola virus disease and were euthanized six to nine days after infection. The authors then took reproductive tissue samples from each macaque and analyzed the samples for signs of Ebola virus infection, organ and tissue damage, and immune responses. They found widespread Ebola virus infection of reproductive organs with minimal tissue immune response or signs of disease. Based on the findings, the authors hypothesize that Ebola virus can persist in these tissues in human survivors, and that the virus may reach seminal fluid in men by infecting immune cells called tissue macrophages. However, it is unclear if the detection of Ebola virus RNA in semen documented in human studies means that infectious virus is present. The authors noted that additional research is needed to learn how Ebola virus persists in these sites, to determine if drugs and vaccines can cure or prevent such infections. To do this, NIAID scientists at NIH are developing a new nonhuman primate model of Ebola virus disease in which monkeys survive infection. Few macaques survive in the current model, making it difficult to study virus persistence and its long-term impacts.

FDA Expands Approval of Imfinzi to Reduce the Risk of Progressing NSCLC


Lung cancer is the leading cause of cancer death in the United States, with an estimated 222,500 new diagnoses and 155,870 deaths in 2017, according to the National Cancer Institute at the National Institutes of Health. The most common type of lung cancer, non-small cell lung cancer (NSCLC), occurs when cancer cells form in the tissues of the lung. Stage III NSCLC means tumors have spread to nearby lymph nodes or into other parts of the body near the lungs.


The FDA has approved Imfinzi (durvalumab) for the treatment of patients with stage III (NSCLC whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). According to FDA, this is the first treatment approved for stage III unresectable NSCLC to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation. For patients with stage III lung cancer that cannot be removed surgically, the current approach to prevent progression is chemoradiation. Although a small number of patients may be cured with the chemoradiation, the cancer may eventually progress. Patients now have an approved therapy that has been shown to keep the cancer from progressing for a longer time after chemoradiation.


Imfinzi targets the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells). By blocking these interactions, Imfinzi may help the body’s immune system attack cancer cells. Imfinzi was previously granted accelerated approval in 2017 for the treatment of certain patients with locally advanced or metastatic bladder cancer. The approval of Imfinzi for the treatment of stage III, unresectable NSCLC was based on a randomized trial of 713 patients whose cancer had not progressed after completing chemotherapy and radiation. The trial measured the length of time the tumors did not have significant growth after starting treatment with Imfinzi or a placebo (progression-free survival). The median progression-free survival for patients taking Imfinzi was 16.8 months compared to 5.6 months for patients receiving a placebo. In addition, the sponsor has agreed to a post-marketing commitment to provide additional information from their study to the FDA about how long patients lived following treatment with Imfinzi after chemotherapy and radiation (overall survival).


Common side effects of Imfinzi in patients with stage III unresectable NSCLC include cough, fatigue, inflammation in the lungs (pneumonitis/radiation pneumonitis), upper respiratory tract infections, difficulty breathing and rash. Serious risks of Imfinzi include immune-mediated side effects, where the body’s immune system attacks healthy cells or organs, such as the lungs (pneumonitis), liver (hepatitis), colon (colitis), hormone-producing glands (endocrinopathies) and kidneys (nephritis). Other serious side effects of Imfinzi include infection and infusion-related reactions. Imfinzi can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception.


The FDA granted this application Priority Review and Breakthrough Therapy designations. Imfinzi is marketed by AstraZeneca.


Korean Cocktail Celebrates the Lunar New Year (Dog)

Year of the Dog, Cocktail made with Vodka, only available in Korea (ROK); ©Joyce Hays, Target Health Inc.


Year of the Dog

Graphic credit: Fanghong – Own work, CC BY-SA 3.0,


We bring you a Korean vodka cocktail to celebrate the New Year with! We raise our glasses to The Republic of Korea, the host country for this year’s winter Olympics. We also give a toast to Mr. and Mrs. Yong Joong Kim, who brought the vodka back from Korea. We give Cheers, to all of our wonderful Asian employees who contribute daily to the feeling of community at THI. ©Joyce Hays, Target Health Inc.


Ingredients: For two delicious Korean vodka cocktails

3 jiggers of Korean vodka

1 cup of ruby red Tropicana grapefruit juice

3 jiggers of Frangelico

3 jiggers Ginger liqueur

1 teaspoon Campari in each glass, after all else is poured in

2 Martini picks (1 per glass)

6 Cocktail cherries, 3 on each pick (per glass)

1 Cara Cara orange, 1 circle cut in half, half per glass

2 spears watermelon (1 per glass)

2 spears cantaloupe (optional) – 1 per glass


This rare vodka, brought back from Korea, enabled us to create an exclusive (with copyright) Korean Cocktail recipe that we share with you. ©Joyce Hays, Target Health Inc.


Above are the 4 basic alcoholic ingredients needed for this vodka cocktail: Absolut Korean (spiced) vodka, Canton Ginger Liqueur, Frangelico Liqueur, and after the above mixture is shaken with ice & with gusto, 1 teaspoon of Campari is gently dropped on the surface of the drink. I learned this secret from a friendly Italian master bartender, now Maitre D’ ©Joyce Hays, Target Health Inc.


You never want to use those bright red totally chemical cocktail cherries. Instead, shop around for slightly more expensive real cherries in their own syrup or sometimes infused in brandy, cognac or (above) bourbon. ©Joyce Hays, Target Health Inc.


After trying out several brands of juice (orange and grapefruit) plus some fizzy citrus, we settled on the above ruby red with pulp. ©Joyce Hays, Target Health Inc.


Cut your fruit, before you do anything else. Cara cara oranges were used because they have peak flavor right now and because their color is really beautiful, as you can see above. ©Joyce Hays, Target Health Inc.



1. Decide what fruit you want to use, then do all the cutting and slicing needed. This is a fun chance to be creative, in the shapes and lengths you make of the fruit.

2. Put all the fruit in each cocktail glass, so you’re free to arrange it any way you want. If you do this after the drink is poured, it’s much harder.

3. In a cocktail shaker, add all the ingredients except for the Campari

4. Shake vigorously.

5. Take cover off shaker and add as many ice cubes as will fit. Shake again with gusto

6. Pour the mixture, through the strainer, into each glass, about 1 inch from the top of the glass rim.

7. Pour a small amount of Campari into a small glass or measuring cup.

8. Place the drink in front of the lucky person about to take a sip. Now dip a teaspoon into the Campari, fill it, and carefully drop the Campari onto the surface of the drink. DO NOT STIR. WAIT until the Campari drops through the rest of the drink and falls to the bottom. The result will be remarkable layers of color, this small amount of Campari adds to the already delicious Korean vodka drink

9. Okay, now sip, smile and be happy in the moment, as life’s struts and frets, fade away.


Enjoy!! ©Joyce Hays, Target Health Inc.


In this photo you can see the layers of color in this delicious Korean cocktail. The Campari is the heaviest liquid, hence, when you carefully drip the one teaspoon, or a tiny bit more of Campari over the top of the mixed cocktail, it finds its way to the very bottom of the glass.


Serve cheesy appetizers with this cocktail. Also, crackers and green and red seedless grapes. And try cutting sweet potatoes and butternut squash into cubes, put on rimmed baking sheet, pour some extra virgin olive oil over the veggies and bake at 375 degrees, until crisp. Serve with toothpicks.


We wish all of our readers a Happy Lunar New Year.  If you are not familiar with the beautiful crossover voice from Kazakhstan, Dimash Kudaibergenov, here he is singing one of his most popular songs: SOS of an Earthly Being in Distress


Dimash Kudaibergenov: Opera 2 

Dimash Kudaibergenov: Adagio


Have a great week everyone!

From Our Table to Yours

Bon Appetit!